Anti-protozoan methods and materials
AssigneeXoma Corporation
InventorLewis H. Lambert, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product.
Claims36
A method of treating a protozoan infection comprising administering to a subject suffering from a protozoan infection an anti-protozoan agent selected from the group consisting of chloroquine, quinine, mefloquine, amodiaquine, primaquine, pyrimethamine, sulfadoxine, sulfadiazine, trimethoprim, pentavalent antimony, pentamidine, amphotericin B, rifampin, metronidazole, ketoconazole, benznidazole and nifurtimox, and a bactericidal/permeability-increasing (BPI) protein product, said BPI protein product being BPI holoprotein, a BPI fragment, a BPI variant, a BPI analog, or a BPI-derived peptide, or dimeric forms thereof, and said anti-protozoan agent and BPI protein product being administered in therapeutically effective amounts.
A method of killing or inhibiting growth of a protozoa comprising contacting said protozoa with an anti-protozoan agent selected from the group consisting of chloroquine, quinine, mefloquine, amodiaquine, primaquine, pyrimethamine, sulfadoxine, sulfadiazine, trimethoprim, pentavalent antimony, pentamidine, amphotericin B, rifampin, metronidazole, ketoconazole, benznidazole and nifurtimox, and a bactericidal/permeability-increasing (BPI) protein product, said BPI protein product being BPI holoprotein, a BPI fragment, a BPI variant, a BPI analog, or a BPI-derived peptide, or dimeric forms thereof, and said anti-protozoan agent and BPI protein product being administered in amounts effective to kill or inhibit growth of said protozoa.
Dependencies are inferred from the claim text.